>> Large study of stomach medicine soothes fears
>> FDA declines novel medicine for anaphylaxis
The Med & Mic™ 09.20.23
MED NEWS blog post from Dr. Maria ON Speaking, LLC
No Cancer Link in Large Study of Zantac
In a retrospective, multinational cohort study, people who took ranitidine (Zanatc) for at least a month were no more likely to develop cancer than those who used other histamine-2 receptor antagonists (H2 blockers). This medicine was the most commonly used treatment for reflux and peptic ulcer disease until 2019 when the FDA found a cancer causing compound in some ranitidine products. (Source: MedPage Today, T. Haelle, 9.19.23)
Nasal Spray for Emergency Allergy Treatment Not Approved
The FDA has declined the approval of a nasal spray which would have been the the first needle-free emergency treatment for allergic reactions. The FDA has requested additional testing, even though its advisory panel recommended approval in May. In the clinical trials, the drug was not tested in people with anaphylaxis due to ethical concerns. The regulatory body would like more data in this patient group. (Reuters, S. Roy, and J. Nidumolu, 9.20.23)
Read Scoop, MD: the Doctor’s Guide to Media Interviews and Opportunities. Click here to read it now on your cell phone.
Get in touch for help with presentations and media interviews at DrMariaOnSpeaking.com.
Remember: this post is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis, or the advice of your own physician. Always check with your own physician or medical professional before trying or implementing any information read here.